Could a common diabetes drug shrink prostate tumors?

NCT ID NCT04887935

Terminated Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This early-stage trial is testing whether dapagliflozin (Farxiga), a drug used for diabetes and heart failure, is safe and tolerable when taken for four weeks before prostate removal surgery in men with localized prostate cancer. The study will also look for signs that the drug may shrink tumors or cause cancer cell death. Only 24 men with intermediate- to high-risk prostate cancer will participate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dapagliflozin (Farxiga)
What this could lead to: If this works, it could point toward a new way to shrink prostate tumors before surgery, potentially improving outcomes.
What could go wrong: This is a very early, small pilot study with only 24 men. It primarily tests safety, not effectiveness, so the drug may not shrink tumors or cause significant benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER OF PROSTATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER OF PROSTATE PROSTATE CANCER

Contacts and locations

Locations

Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.